Latest Data from Landmark STORM-PE Randomized Controlled Trial Demonstrate that CAVT with Anticoagulation Significantly Improves Functional Outcomes for Patients with Pulmonary Embolism

Accessibility StatementSkip Navigation ALAMEDA, Calif., Nov. 3, 2025 /PRNewswire/ --Â Penumbra, Inc. (NYSE: PEN) announced additional results of the ground- breaking STORM-PE randomized controlled trial (RCT), which found that the use of computer assisted vacuum thrombectomy (CAVTâ"¢) with anticoagulation achieved significantly greater improvements in thrombus burden reduction, heart rate, oxygen requirement, and functional outcomes compared to anticoagulation alone in patients with acute intermediate-high ...